Back

A combination of EWSR1-FLI1 with loss of one EWSR1 allele promotes damage in the mitotic spindle and sensitization to microtubule-destabilizing agent

Schulz, E.;Azuma, M.

2026-06-19 Cancer Biology
10.64898/2026.06.15.732411 bioRxiv
Show abstract

Microtubule-destabilizing agents (MDAs) and microtubule-stabilizing agents (MSAs) are commonly used chemotherapeutic agents due to its activity to induce cell death by compromising the dynamics of spindles during mitosis. Ewing sarcoma, the second most common pediatric bone cancer, is known to selectively respond to MDAs as a first-line treatment, but not to MSAs. Ewing sarcoma cells carry an aberrant EWSR1-FLI1 fusion gene and only one wildtype EWSR1 allele. To investigate the origin of this MDA sensitivity, we used an (AID-EWSR1/wt: EWSR1-FLI1-mCherry/wt) cell line that enables conditional induction of EWSR1-FLI1 expression (Tet-On system) and EWSR1 knockdown derived from one EWSR1 allele (auxin-degron system). A combination of EWSR1-FLI1 expression and EWSR1 knockdown induces apoptosis upon nocodazole treatment, a type of MDA. Our study revealed that the mitotic spindles of Ewing sarcoma cells (A673, RD-ES and SK-ES1) contain elevated levels of tubulin damage, visualized with GTP-tubulin, compared to mesenchymal stem cells (MSC). Consistently, the combination of EWSR1-FLI1 expression and EWSR1 knockdown in (AID-EWSR1/wt: EWSR1-FLI1-mCherry/wt) cell line also leads to an increased incidence of damage in mitotic spindles. Together, we propose that the sensitivity of Ewing sarcoma cells is derived from the increased levels of damage to mitotic spindles caused by EWSR1-FLI1 expression and EWSR1 knockdown.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
PLOS ONE
5266 papers in training set
Top 8%
21.0%
2
Cancers
213 papers in training set
Top 0.1%
17.1%
3
Scientific Reports
3612 papers in training set
Top 2%
14.6%
50% of probability mass above
4
International Journal of Molecular Sciences
494 papers in training set
Top 7%
2.0%
5
Biomedicines
67 papers in training set
Top 0.8%
2.0%
6
Bone
25 papers in training set
Top 0.2%
1.9%
7
eLife
5828 papers in training set
Top 46%
1.9%
8
Frontiers in Oncology
103 papers in training set
Top 2%
1.3%
9
Oncotarget
18 papers in training set
Top 0.2%
1.3%
10
Disease Models & Mechanisms
20 papers in training set
Top 0.2%
1.3%
11
Molecular Oncology
55 papers in training set
Top 0.9%
1.2%
12
Cells
249 papers in training set
Top 5%
1.1%
13
Biology Open
156 papers in training set
Top 3%
1.0%
14
Experimental Cell Research
28 papers in training set
Top 0.5%
1.0%
15
Cell Cycle
17 papers in training set
Top 0.4%
1.0%
16
BMC Molecular and Cell Biology
16 papers in training set
Top 0.1%
1.0%
17
Heliyon
152 papers in training set
Top 7%
1.0%
18
Molecular Therapy Nucleic Acids
39 papers in training set
Top 0.8%
1.0%
19
iScience
1154 papers in training set
Top 38%
0.7%
20
Archives of Clinical and Biomedical Research
28 papers in training set
Top 2%
0.5%
21
Frontiers in Physiology
106 papers in training set
Top 4%
0.5%
22
Molecular Cancer Therapeutics
40 papers in training set
Top 1%
0.5%
23
Cell Death Discovery
58 papers in training set
Top 2%
0.5%
24
Oncogene
85 papers in training set
Top 2%
0.5%
25
Biochemistry and Biophysics Reports
30 papers in training set
Top 2%
0.5%